Axogen Reports 26% Revenue Growth in Q3 and Forecasts $290 Million for 2026
Axogen (AXGN) reported third-quarter revenue of $75.8 million, representing a 26.2% increase compared to the same period in 2025. Growth was driven significantly by its breast segment, which expanded by more than 50% year-over-year, while extremities, OMF (Oral, Maxillofacial), and head and neck segments saw a combined growth of 10.7%. Looking ahead, the company has provided an optimistic long-term outlook, forecasting at least $290 million in revenue for 2026. This projection includes an additional $7 million contribution from BioCircuit. Furthermore, Axogen is planning to expand its market presence into prostate development starting in 2027.
Tickers: $AXGN
Topics: quarterly earnings revenue growth segment performance